Repligen Corporation to Report Q4 2025 Financial Results on February 24, 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Should l Buy RGEN?
Source: Newsfilter
- Earnings Release Schedule: Repligen Corporation will report its Q4 2025 financial results on February 24, 2026, with a press release expected before market open, providing investors with timely financial updates and business insights.
- Conference Call Details: The company will host a conference call at 8:30 a.m. ET, allowing domestic callers to dial toll-free (800) 715-9871 and international callers to use (646) 307-1963, facilitating investor engagement and detailed discussions on financial results.
- Webcast Access: Investors can access the conference call via a webcast on the company's Investor Relations section, ensuring global investors can receive real-time critical information, thereby enhancing transparency and communication.
- Company Overview: Repligen is a global life sciences company focused on developing and commercializing bioprocessing technologies that serve biopharmaceutical developers and contract development manufacturing organizations, showcasing its innovative capabilities and market impact in the biopharmaceutical sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RGEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RGEN
Wall Street analysts forecast RGEN stock price to rise
12 Analyst Rating
9 Buy
3 Hold
0 Sell
Strong Buy
Current: 132.630
Low
165.00
Averages
189.00
High
207.00
Current: 132.630
Low
165.00
Averages
189.00
High
207.00
About RGEN
Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Repligen Corporation to Report Q4 2025 Financial Results on February 24, 2026
- Earnings Release Schedule: Repligen Corporation will report its Q4 2025 financial results on February 24, 2026, with a press release expected before market open, providing investors with timely financial updates and business insights.
- Conference Call Details: The company will host a conference call at 8:30 a.m. ET, allowing domestic callers to dial toll-free (800) 715-9871 and international callers to use (646) 307-1963, facilitating investor engagement and detailed discussions on financial results.
- Webcast Access: Investors can access the conference call via a webcast on the company's Investor Relations section, ensuring global investors can receive real-time critical information, thereby enhancing transparency and communication.
- Company Overview: Repligen is a global life sciences company focused on developing and commercializing bioprocessing technologies that serve biopharmaceutical developers and contract development manufacturing organizations, showcasing its innovative capabilities and market impact in the biopharmaceutical sector.
See More
RGEN Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: RGEN's 52-week low is $102.965 per share, while the high is $175.77, with the last trade at $139.66, indicating significant price movement within this range and reflecting market interest and investor sentiment changes.
- Technical Indicator Observation: The current price of $139.66 is below the 200-day moving average, suggesting potential downward pressure on the stock in the short term, prompting investors to monitor market dynamics for risk assessment.
- Market Sentiment Evaluation: Although the current stock price is positioned in the middle of the 52-week range, the significant gap from the high may affect investor confidence and willingness to buy, necessitating close attention to market reactions.
- Investment Strategy Recommendation: Investors considering RGEN stock should integrate technical analysis and market trends to evaluate its investment value at the current price level, thereby formulating a sound investment strategy.
See More
UBS Raises Repligen's Price Target to $200, Citing 20% Order Growth
- Price Target Increase: UBS raised Repligen's price target from $190 to $200 while maintaining a Buy rating, reflecting confidence in the company's leadership in the bioprocessing sector recovery.
- Strong Order Growth: Repligen reported over 20% order growth and is expanding its footprint in Edge manufacturing, positioning itself as a core beneficiary as biopharma companies reshore production closer to primary markets by 2026.
- New Product Launch: On December 16, Repligen launched three new high-performance chromatography resins designed to meet next-gen bioprocessing needs, particularly for viral vectors in gene therapy, thereby enhancing its protein portfolio.
- Technological Innovation: The new resins utilize Tantti DuloCore base bead technology to improve molecule stability, accelerate product development, and enhance overall process economics for gene therapy developers, thereby increasing processing efficiency for complex biotherapeutic workflows.
See More
Repligen Elects Martin Madaus as Board Chair Effective March 13
- Board Transition: Repligen announced the election of Martin Madaus as chair of the board effective March 13, following the retirement of Tony Hunt, indicating a strategic leadership shift within the company.
- Experienced Leadership: Having served as a director since February 2023, Madaus brings 36 years of industry experience, which not only enhances the company's management perspective but also aids in driving future growth initiatives.
- Continuity in Advisory Role: Tony Hunt will remain as an advisor until March 2027, ensuring stability and continuity during the transition period, which helps maintain investor confidence in the company's direction.
- Market Reaction: In pre-market trading on Nasdaq, Repligen's stock rose by 0.33% to $170, reflecting positive market sentiment towards the new chair and potentially fostering future growth for the company.
See More
Canaccord Genuity Keeps Hold Rating on Repligen and Increases Price Target to $165
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform is designed to help traders succeed in the stock market with accurate intelligence.
See More
Repligen (RGEN) Exceeds Expectations in Q3 Earnings and Revenue
Earnings Performance: Repligen (RGEN) reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.42, and showing a year-over-year increase from $0.43. The company has surpassed consensus EPS estimates three times in the last four quarters.
Revenue Growth: The company achieved revenues of $188.81 million for the quarter, surpassing the Zacks Consensus Estimate by 4.18% and increasing from $154.87 million a year ago, also topping revenue estimates three times in the last four quarters.
Stock Outlook: Despite an 11.9% increase in shares since the beginning of the year, Repligen is currently rated Zacks Rank #4 (Sell), indicating expected underperformance in the near future due to unfavorable earnings estimate revisions.
Industry Context: The Medical - Biomedical and Genetics industry, where Repligen operates, ranks in the top 37% of Zacks industries, suggesting that overall industry performance can significantly impact individual stock performance.
See More
Repligen Corporation to Report Q4 2025 Financial Results on February 24, 2026
- Earnings Release Schedule: Repligen Corporation will report its Q4 2025 financial results on February 24, 2026, with a press release expected before market open, providing investors with timely financial updates and business insights.
- Conference Call Details: The company will host a conference call at 8:30 a.m. ET, allowing domestic callers to dial toll-free (800) 715-9871 and international callers to use (646) 307-1963, facilitating investor engagement and detailed discussions on financial results.
- Webcast Access: Investors can access the conference call via a webcast on the company's Investor Relations section, ensuring global investors can receive real-time critical information, thereby enhancing transparency and communication.
- Company Overview: Repligen is a global life sciences company focused on developing and commercializing bioprocessing technologies that serve biopharmaceutical developers and contract development manufacturing organizations, showcasing its innovative capabilities and market impact in the biopharmaceutical sector.
See More
RGEN Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: RGEN's 52-week low is $102.965 per share, while the high is $175.77, with the last trade at $139.66, indicating significant price movement within this range and reflecting market interest and investor sentiment changes.
- Technical Indicator Observation: The current price of $139.66 is below the 200-day moving average, suggesting potential downward pressure on the stock in the short term, prompting investors to monitor market dynamics for risk assessment.
- Market Sentiment Evaluation: Although the current stock price is positioned in the middle of the 52-week range, the significant gap from the high may affect investor confidence and willingness to buy, necessitating close attention to market reactions.
- Investment Strategy Recommendation: Investors considering RGEN stock should integrate technical analysis and market trends to evaluate its investment value at the current price level, thereby formulating a sound investment strategy.
See More
UBS Raises Repligen's Price Target to $200, Citing 20% Order Growth
- Price Target Increase: UBS raised Repligen's price target from $190 to $200 while maintaining a Buy rating, reflecting confidence in the company's leadership in the bioprocessing sector recovery.
- Strong Order Growth: Repligen reported over 20% order growth and is expanding its footprint in Edge manufacturing, positioning itself as a core beneficiary as biopharma companies reshore production closer to primary markets by 2026.
- New Product Launch: On December 16, Repligen launched three new high-performance chromatography resins designed to meet next-gen bioprocessing needs, particularly for viral vectors in gene therapy, thereby enhancing its protein portfolio.
- Technological Innovation: The new resins utilize Tantti DuloCore base bead technology to improve molecule stability, accelerate product development, and enhance overall process economics for gene therapy developers, thereby increasing processing efficiency for complex biotherapeutic workflows.
See More
Repligen Elects Martin Madaus as Board Chair Effective March 13
- Board Transition: Repligen announced the election of Martin Madaus as chair of the board effective March 13, following the retirement of Tony Hunt, indicating a strategic leadership shift within the company.
- Experienced Leadership: Having served as a director since February 2023, Madaus brings 36 years of industry experience, which not only enhances the company's management perspective but also aids in driving future growth initiatives.
- Continuity in Advisory Role: Tony Hunt will remain as an advisor until March 2027, ensuring stability and continuity during the transition period, which helps maintain investor confidence in the company's direction.
- Market Reaction: In pre-market trading on Nasdaq, Repligen's stock rose by 0.33% to $170, reflecting positive market sentiment towards the new chair and potentially fostering future growth for the company.
See More
Canaccord Genuity Keeps Hold Rating on Repligen and Increases Price Target to $165
Real-time Intelligence: Benzinga Pro offers traders the fastest news alerts to stay updated on market movements.
Exclusive Content: Subscribers gain access to unique stories and insights generated by Benzinga reporters.
Community of Traders: Over 10,000 serious traders are part of the Benzinga Pro community, enhancing their trading strategies.
Market Winning Tools: The platform is designed to help traders succeed in the stock market with accurate intelligence.
See More
Repligen (RGEN) Exceeds Expectations in Q3 Earnings and Revenue
Earnings Performance: Repligen (RGEN) reported quarterly earnings of $0.46 per share, exceeding the Zacks Consensus Estimate of $0.42, and showing a year-over-year increase from $0.43. The company has surpassed consensus EPS estimates three times in the last four quarters.
Revenue Growth: The company achieved revenues of $188.81 million for the quarter, surpassing the Zacks Consensus Estimate by 4.18% and increasing from $154.87 million a year ago, also topping revenue estimates three times in the last four quarters.
Stock Outlook: Despite an 11.9% increase in shares since the beginning of the year, Repligen is currently rated Zacks Rank #4 (Sell), indicating expected underperformance in the near future due to unfavorable earnings estimate revisions.
Industry Context: The Medical - Biomedical and Genetics industry, where Repligen operates, ranks in the top 37% of Zacks industries, suggesting that overall industry performance can significantly impact individual stock performance.
See More
